Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
The European Parliament is about to sign off corrigenda to the Medical Devices and IVD Regulations. The headline news is a longer transition period for a huge swathe of class I products, but there are other changes too.
Latest From Policy, Regulation & Europe
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Twenty-eight guidance documents have been posted on the tracker since its last update.
The two-year delay to Eudamed was a Commission decision. Now the competent authorities are fighting back and the issue is to be discussed at the level of the Council of the European Union on December 9 to avoid “heavily burdensome administrative transitional solutions.”
With six months left to the full implementation of the EU’s Medical Devices Regulation, there are a couple of big shifts taking place in the way it is being applied. Following news of the Eudamed database two-year delay, confirmation looks imminent that many more products will avoid having to comply with the MDR by next May. But will this plan sufficiently alleviate implementation pressures?
Eudamed Timelines: Unraveling Contradictory Legislation To Understand How The Deadlines Apply – A Lawyer’s View
The new version of the Eudamed database has been delayed – the European Commission says by two years. But how extensive is the delay? Fieldfisher partner, Alison Dennis, explains why the medtech sector needs to be cautious about how it interprets the latest developments.
NHS England’s Long Term Plan puts much emphasis on better use of diagnostic tools in health-care delivery. The UK medtech industry is now pressing for a strategy to ensure that these technologies are factored into all patient pathways. It says the data derived will be used to improve patient outcomes and system efficiency.
Ireland’s drug and medical device regulator is seeking stakeholder views on what its priorities should be over the next five years, given the uncertainties of Brexit and impending regulatory changes.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.